MA57379B1 - Modulateurs du recepteur alpha associe aux oestrogenes (err-alpha) - Google Patents
Modulateurs du recepteur alpha associe aux oestrogenes (err-alpha)Info
- Publication number
- MA57379B1 MA57379B1 MA57379A MA57379A MA57379B1 MA 57379 B1 MA57379 B1 MA 57379B1 MA 57379 A MA57379 A MA 57379A MA 57379 A MA57379 A MA 57379A MA 57379 B1 MA57379 B1 MA 57379B1
- Authority
- MA
- Morocco
- Prior art keywords
- alpha
- estrogen
- modulators
- err
- receptor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
La présente invention concerne des composés de formule i et leurs sels pharmaceutiquement acceptables. Ces composés peuvent être utilisés en tant que modulateurs du récepteur alpha associé aux oestrogènes (erra) et ont une utilité dans le traitement de maladies ou d'affections médiées par erra. (i)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19204189 | 2019-10-18 | ||
| PCT/EP2020/079166 WO2021074365A1 (fr) | 2019-10-18 | 2020-10-16 | MODULATEURS DU RÉCEPTEUR ALPHA ASSOCIÉ AUX OESTROGÈNES (ERRα) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA57379B1 true MA57379B1 (fr) | 2024-02-29 |
Family
ID=68296174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA57379A MA57379B1 (fr) | 2019-10-18 | 2020-10-16 | Modulateurs du recepteur alpha associe aux oestrogenes (err-alpha) |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240150342A1 (fr) |
| EP (1) | EP4045503B1 (fr) |
| JP (1) | JP2023501081A (fr) |
| KR (1) | KR20220084355A (fr) |
| CN (1) | CN114630827A (fr) |
| AU (1) | AU2020365434A1 (fr) |
| BR (1) | BR112022006906A2 (fr) |
| CA (1) | CA3151045A1 (fr) |
| CO (1) | CO2022003829A2 (fr) |
| HR (1) | HRP20240237T1 (fr) |
| IL (1) | IL291523B2 (fr) |
| MA (1) | MA57379B1 (fr) |
| MX (1) | MX2022004394A (fr) |
| RS (1) | RS64986B1 (fr) |
| WO (1) | WO2021074365A1 (fr) |
| ZA (1) | ZA202203025B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117836296A (zh) * | 2021-08-03 | 2024-04-05 | 百济神州有限公司 | 吡唑并吡啶酮化合物 |
| WO2023165525A1 (fr) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Inhibiteurs de diacylglycérol kinase (dgk) alpha et leurs utilisations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2129668A1 (fr) * | 2007-03-07 | 2009-12-09 | Janssen Pharmaceutica N.V. | Phénoxy thiazolidinediones substituées comme modulateurs de récepteur alpha d' strogène |
| EP2464647B1 (fr) * | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindoles en tant qe modulateurs du recepteur btk et leur utilisation |
| AR101528A1 (es) * | 2013-03-14 | 2016-12-28 | Abbvie Inc | Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina |
-
2020
- 2020-10-16 HR HRP20240237TT patent/HRP20240237T1/hr unknown
- 2020-10-16 RS RS20231236A patent/RS64986B1/sr unknown
- 2020-10-16 MA MA57379A patent/MA57379B1/fr unknown
- 2020-10-16 MX MX2022004394A patent/MX2022004394A/es unknown
- 2020-10-16 AU AU2020365434A patent/AU2020365434A1/en active Pending
- 2020-10-16 US US17/754,902 patent/US20240150342A1/en active Pending
- 2020-10-16 EP EP20792415.0A patent/EP4045503B1/fr active Active
- 2020-10-16 WO PCT/EP2020/079166 patent/WO2021074365A1/fr active Application Filing
- 2020-10-16 JP JP2022522032A patent/JP2023501081A/ja active Pending
- 2020-10-16 BR BR112022006906A patent/BR112022006906A2/pt unknown
- 2020-10-16 CN CN202080072119.3A patent/CN114630827A/zh active Pending
- 2020-10-16 CA CA3151045A patent/CA3151045A1/fr active Pending
- 2020-10-16 KR KR1020227016464A patent/KR20220084355A/ko unknown
- 2020-10-16 IL IL291523A patent/IL291523B2/en unknown
-
2022
- 2022-03-14 ZA ZA2022/03025A patent/ZA202203025B/en unknown
- 2022-03-29 CO CONC2022/0003829A patent/CO2022003829A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS64986B1 (sr) | 2024-01-31 |
| US20240150342A1 (en) | 2024-05-09 |
| AU2020365434A1 (en) | 2022-05-26 |
| CN114630827A (zh) | 2022-06-14 |
| KR20220084355A (ko) | 2022-06-21 |
| CO2022003829A2 (es) | 2022-07-08 |
| EP4045503C0 (fr) | 2023-12-06 |
| MX2022004394A (es) | 2022-05-18 |
| EP4045503B1 (fr) | 2023-12-06 |
| CA3151045A1 (fr) | 2021-04-22 |
| IL291523B2 (en) | 2023-12-01 |
| IL291523A (en) | 2022-05-01 |
| EP4045503A1 (fr) | 2022-08-24 |
| IL291523B1 (en) | 2023-08-01 |
| BR112022006906A2 (pt) | 2022-07-05 |
| ZA202203025B (en) | 2023-12-20 |
| HRP20240237T1 (hr) | 2024-05-10 |
| JP2023501081A (ja) | 2023-01-18 |
| WO2021074365A1 (fr) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA33552B1 (fr) | Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques | |
| MA42410B1 (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA44674B1 (fr) | Inhibiteurs de bromodomaine | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA39554A3 (fr) | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock | |
| MA42295B1 (fr) | Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| TN2012000192A1 (fr) | N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase | |
| MA57379B1 (fr) | Modulateurs du recepteur alpha associe aux oestrogenes (err-alpha) | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA35753B1 (fr) | Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2 | |
| MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA37891A1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
| MA35184B1 (fr) | Antagonistes de trpv4 | |
| MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
| MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
| MA46229A (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA38810B1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA42769B1 (fr) | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA38694B1 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
| MA39926B1 (fr) | Dérivés de dihétérocycle liés à cycloalkyle | |
| MA46965B1 (fr) | Modulateurs de gamma ror (rory) |